Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and despite cure
rates exceeding 90% in children, it remains an important cause of morbidity and mortality in …

Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL), also referred to as
BCR-ABL1–like ALL, is a high-risk subset with a gene expression profile that shares …

Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL) is a high-risk
subtype characterized by genomic alterations that activate cytokine receptor and kinase …

PDGFRA and PDGFRB are classical proto-oncogenes that encode receptor tyrosine kinases
responding to platelet-derived growth factor (PDGF). PDGFRA mutations are found in …

Philadelphia chromosome–like acute lymphoblastic leukemia (Ph-like ALL; BCR-ABL1–like
ALL) in children with National Cancer Institute (NCI) intermediate-or high-risk (HR) ALL is …

Purpose Minimal residual disease (MRD) and genetic abnormalities are important risk
factors for outcome in acute lymphoblastic leukemia. Current risk algorithms dichotomize …

Philadelphia chromosome (Ph)–like B-cell acute lymphoblastic leukemia (Ph-like ALL) is
associated with activated JAK/STAT, Abelson kinase (ABL), and/or phosphatidylinositol 3 …

A 9-year-old boy presented with a 3-month history of progressive pallor and upper
respiratory tract infection. He had no hepatosplenomegaly or mediastinal mass. An …

New therapies for Philadelphia chromosome–like acute lymphoblastic leukemia (Ph-like
ALL) patients are urgently needed. The genetic landscape of Ph-like ALL is characterized by …

Rapid advances in genomics have opened unprecedented possibilities to explore the
mutational landscapes in malignant diseases, such as B-cell acute lymphoblastic leukemia …